Bod Science Past Earnings Performance
Past criteria checks 0/6
Bod Science's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 20.2% per year.
Key information
-4.2%
Earnings growth rate
14.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 20.2% |
| Return on equity | n/a |
| Net Margin | -239.5% |
| Last Earnings Update | 30 Jun 2023 |
Revenue & Expenses BreakdownBeta
How Bod Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -8 | 4 | 3 |
| 31 Mar 23 | 4 | -7 | 4 | 3 |
| 31 Dec 22 | 4 | -6 | 4 | 2 |
| 30 Sep 22 | 5 | -6 | 5 | 2 |
| 30 Jun 22 | 5 | -5 | 5 | 2 |
| 31 Mar 22 | 6 | -5 | 5 | 2 |
| 31 Dec 21 | 8 | -5 | 5 | 2 |
| 30 Sep 21 | 8 | -5 | 5 | 2 |
| 30 Jun 21 | 7 | -4 | 5 | 2 |
| 31 Mar 21 | 7 | -4 | 4 | 2 |
| 31 Dec 20 | 7 | -5 | 4 | 2 |
| 30 Sep 20 | 7 | -5 | 4 | 2 |
| 30 Jun 20 | 6 | -5 | 3 | 2 |
| 31 Mar 20 | 4 | -6 | 4 | 2 |
| 31 Dec 19 | 2 | -6 | 4 | 1 |
| 30 Sep 19 | 2 | -7 | 5 | 2 |
| 30 Jun 19 | 1 | -8 | 5 | 2 |
| 31 Mar 19 | 1 | -6 | 4 | 2 |
| 31 Dec 18 | 1 | -5 | 3 | 2 |
| 30 Sep 18 | 1 | -4 | 3 | 1 |
| 30 Jun 18 | 1 | -4 | 2 | 1 |
| 31 Mar 18 | 1 | -3 | 2 | 1 |
| 31 Dec 17 | 1 | -3 | 2 | 0 |
| 30 Sep 17 | 1 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -3 | 2 | 0 |
| 31 Mar 17 | 0 | -3 | 2 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | 0 | 0 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
Quality Earnings: BOD is currently unprofitable.
Growing Profit Margin: BOD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOD is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare BOD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: BOD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.